~~<i id='F3E5F9D2B3'><strike id='F3E5F9D2B3'><tt id='F3E5F9D2B3'><pre id='F3E5F9D2B3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

leisure time

author：hotspot 2025-09-28 02:30:49 - browse：258

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： R1 RCM gets $5.8 billion buyout offer from private equity firm

focus

entertainment

hotspot

leisure time

focus

Wikipedia

MollyFerguson/STATAnnovisBiohadmybiotechbull%^&!meterrunningredafteritmadealatechangetothedesign

WSS

A new nitrogen execution bill also undermines medical licensing

R1 RCM gets $5.8 billion buyout offer from private equity firm

Carbon Health diabetes program, a test of data

The Harvard botanist who searched for psychedelics in the Amazon

Alabama IVF ruling threatens families facing fatal genetic disease

What is STAT's opinion section for?

explore

leisure time

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medicare inequities exacerbate Puerto Rico’s health disparities

Wildfire smoke exposes gaps in outdoor worker protections

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Continuity nursing helped my family in our darkest PICU moments

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Supreme Court strikes down use of affirmative action

Ventyx halts psoriasis drug development after lackluster trial results

DIEP, the 'gold standard' of breast reconstruction, is under threat

How state and local governments are sidelining science

entertainment

PBM reform efforts get punted in Congress

Why palliative psychiatry is worth discussing

Cancer diagnosis changes perspective doctor, former hospital CEO

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Alabama frozen embryo ruling has major implications for IVF clinics

NIH study of ME/CFS points to clear biological hallmarks

hotspot

leisure time

focus

Wikipedia